NanoCarrier says basic agreement on international joint development of NC-6004 to treat head and neck cancer
May 15 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says it entered into an agreement with the NC-6004 out-licensee, Orient Europharma Co Ltd <<<4120.TWO>>>, aimed at the Asian region, to integrate clinical development of NC-6004 for the treatment of head and neck cancer .Says two entities will conclude a basic agreement for additional licensing and joint development of NC-6004 in regions such as Europe and the United States.
Latest Key Developments inBiotechnology
- Cyclerion Therapeutics Files For Offering Of Up To 11.55 Mln Shares Of Common Stock By The Selling Stockholders
- Seres Therapeutics Says Board Appointed Marcus Chapman As Principal Financial And Accounting Officer
- Prothena Reports Results From The Phase 3 Vital Amyloidosis Study Of Neod001 In Al Amyloidosis
- Mainstay Medical Says Primary Endpoint Of Reactiv8-B Clinical Trial Was Not Achieved